Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Gyre Therapeutics reported Q1 2026 revenue of $22.5 million, up 2% year-over-year, but posted a GAAP net loss of $9.9 million or $(0.10) per share driven by increased R&D, acquisition costs, and stock-based compensation. The company reaffirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million and ended the quarter with $79.2 million in total cash, cash equivalents, and deposits. Operationally, Gyre completed the acquisition of Cullgen Inc. in an approximately $300 million all-stock transaction, expanding its capabilities into targeted protein degradation for cancer and inflammatory diseases.
Key figures
- Revenue
- 22500000
- Guidance
- Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed
- Revenue Yoy
- 2%
- Deal Value Usd
- 300000000
- Net loss
- 9900000
- Etuary sales
- 21000000
- Cash position
- 79200000
- Operating loss
- 9400000
- Transaction costs
- 2500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.